Leuprolide Acetate

Subscribe to Fred Hutch News You will receive a monthly newsletter from us about our innovative research and compassionate care as well as updates on events and other helpful tools and tips. You may unsubscribe at any time. There are 18 million cancer survivors in the United States, thanks to advances in care and treatment. Cancers that used to be death sentences are now treatable, but the effects of chemotherapy, radiation and surgery can last long after treatment ends. An emerging field of cancer care called survivorship focuses on helping people manage the short- and long-term or late effects of cancer treatment. On our Fred Hutch podcast, From Bench to Bedside and Beyond, Hutch News writers/editors Bonnie Rochman and Diane Mapes explore the many facets of survivorship in a new series that dives deep into what it means — physically, emotionally and spiritually — to survive cancer. Key takeaways: The term “survivor” applies to people from the moment of diagnosis. Mapes shares her experience as a breast cancer survivor and advocate Barb Regis, PA-C, discusses her melanoma treatment and how it inspired her to help launch the Survivorship Clinic at Fred Hutch. Why Regis shares her own story of survival with the patients she cares for What patients can expect at the Survivorship Clinic This initial episode is timed to coincide with National Cancer Survivors Day, held annually on the first Sunday in June. Find out about Fred Hutch’s survivorship offerings, learn more about survivorship issues from the American Cancer Society and explore the National Cancer Institute’s Survivorship Resources. Listen to the audio interview Libsyn | Spotify | Apple Podcasts | Amazon Podcasts | YouTube Tune in for more episodes of From Bench to Bedside and Beyond. And if you’re interested in being a guest, please reach out to brochman@fredhutch.org. Transcript: Bonnie Rochman Welcome to From Bench to Bedside and Beyond. I'm Bonnie Rochman. Diane Mapes I'm Diane Mapes. Bonnie Rochman And we're writers at Fred Hutch Cancer Center. And today we're introducing a podcast series about survivorship. So survivorship is a pretty new concept as we've talked about, Diane, and certainly it's a new area of focus for cancer centers like Fred Hutch. And that's because for years and years and years, people didn't actually survive a cancer diagnosis. But with advances in treatment and the tireless research that's going on right here at Fred Hutch and around the country at comprehensive cancer centers, more and more people are starting to survive cancer and living with cancer. In fact, there are now 18 million cancer survivors in the United States alone. And sobecause of that, our survivorship programs are growing. Now, a lot of people might say, what's a survivorship program? And we're going to get to that. So we'll tell you how Fred Hutch is evolving its survivorship program and actually what a survivorship program is in the first place in a later episode. But for now, we're going to really focus on what survivorship means to someone who has firsthand experience with it — Diane Mapes, who was diagnosed with breast cancer 15 years ago. Diane, take it away. What do you think about the term? Diane Mapes Well, we need some kind of term to describe what happens to you after you're diagnosed with cancer. They came up with survivorship. I don't have a problem with it. Some people do, particularly the people who have metastatic or stage 4 cancer, and many feel that they're not actually going to survive, per se, their cancer. But other people really like the term. When you're diagnosed with cancer, you become a survivor automatically. Thank you. You're welcome. Yeah, that's the American Cancer Society's definition. Good enough. I was diagnosed with lobular breast cancer in 2011, early 2011, and had sort of the full Monty when it comes to breast cancer treatment. I had a double mastectomy. I had tumors in both breasts, didn't have a choice. I had chemotherapy. Then I had about six and a half weeks of daily radiation. You do get weekends off for good behavior. And then I had 10 years of anti-hormone treatments. And then, of course, there was also reconstruction, which involved multiple surgeries. So the more treatment you have, the more you are surviving, so to speak. So I went through all of that in 2011. Treatment lasted pretty much the full year. About three years later in 2014, I came to work at Fred Hutch because I was really mad that I had followed all the rules, got all the mammograms, got all of those, had lots and lots of scans and everything was always very clear. I had followed those rules, but cancer did not follow those rules. So I came here to write about cancer research, to write about the cancer experience, trying to help make sense of it for people, or better yet, help them avoid it. So, it's complicated. You're not really surviving just cancer. You're actually surviving a lot of things. You're surviving being diagnosed with cancer. You're surviving the cancer treatment, primarily. You're surviving the U.S. healthcare system, straight-up learning curve, if you've never been in the hospital before. You're surviving financial toxicity because of the high cost of care. You're surviving the PTSD of getting diagnosed and all the immediate side effects that you get from your treatment, as well as the long-term side effects that you can get from a treatment, which can be physiological, emotional, psychological. Again, I mentioned financial toxicity. So you're surviving a lot. Basically, your body has betrayed you on a cellular level. So you come away with a few trust issues, shall we say. Bonnie Rochman And we're going to go into, we're going to break all of those issues down in future episodes. But I want to circle back to something you just said about survivorship. Sowhen we first started kind of rolling this idea around in our heads, one thing that you said that really stuck with me is you're not surviving the cancer. And I'm like, wait, what do you mean? You're surviving the treatment. And you just listed, I think, four different treatments that you underwent. So I thought it could be valuable to talk a little bit about how cancer is a conglomeration of different diseases, even within just breast cancer. It's a different disease for every person. Diane Mapes It's a different disease for everybody. Bonnie Rochman And the treatment is personalized to what your specific cancer is, what your needs are, what your state is. Yeah. It should be. And so can we talk a little bit about the various kinds of cancer treatment and what they can do? Diane Mapes First what I would like to differentiate is I think a lot of people get confused between early stage and late stage cancer. There's other names for it too. You've heardadvanced cancer, metastatic disease, stage 4. In England and the UK, they call it secondary, secondary cancer. It means the cancer has spread beyond the original primary location, your breast, your colon, your lung, you know, your throat, and it's traveled to other organs of the body. Early stage patients rarely are sick from their cancer. I was stage 3, had no idea. Never felt healthier in my life, right? So you don't really have side effects if you're early stage. I, as I said, I got all my mammograms. Everything was always clear, but since I had lobular cancer, which does not make tumors, it doesn't stick together and make a clump. It grows in lines. So a mammogram didn't pick it up. And because I had dense breast tissue, mammograms didn't see that because cancer appears white, and dense breast tissue appears white. So it gets lost in there. So there's a really big difference between your cancer experience if you're diagnosed with early stage and your cancer experience if you were diagnosed with late stage. The thing is you may not experience any side effects of cancer itself when you're early stage. I noticed a change in my breast. That drove the whole, you know, scanning and diagnosis and all. Bonnie Rochman That's what kind of tipped you off that something may be going on. Diane Mapes There was a change in my breasts. It was just a little tiny dent, a little tuck. Looked like nothing. I could have completely ignored it, and I might not be here. But I followed up. Doc said, hey, you're due for a mammogram anyway. Let's get you in for one of those, right? So again though, I had never felt healthier in my life, so it was very counterintuitive to be feeling so healthy and to walk my healthy body into the surgical suite and have body parts removed. What I wanted to point out though, is that I understand why people hesitate about doing the traditional cancer treatment. Because again, if you feel healthy, it is really counterintuitive to have doctors telling you, you have to remove those body parts, you have to do this, you have to do that. So I understand why people will look for alternative treatments. The problem is they do not work. You have to do the treatment that is proved to be effective and evidence-based. Otherwise, you know, you don't make it...We're hearing a lot about early onset colorectal cancers, people under 50. Same thing happens with breast cancer with moms. Postpartum breast cancer, a new mom will develop breast cancer in her 30s. After having a child, stage 4 patients, they might have painand they might be experiencing cancer pain and cancer debilitation. They might have back pain or a blinding headache or shortness of breath. The questions, these questions, are the ones that pop up every time a cancer survivor shows up for their follow-up appointment. They say, do you have any shortness of breath, have you experienced a fall, do you have any pain anywhere? Bonnie Rochman They're not just kind of interested in you. These are very specific targeted questions. Diane Mapes These are specifically targeted questions to find out if you have a metastatic recurrence somewhere in your body where cancer has invaded other organs like your lungs, your brain, your bones. So that's what that is. So for early stagers, it's all about the side effects of treatment and the aftermath of treatment and the surgery and diagnosisand PTSD. With late stagers, they have the treatment that they're dealing with. The PTSD of a diagnosis and a terminal diagnosis, but they're also dealing with the pain and the hardship of cancer itself on top of the treatment that they're getting. They're dealing with that on a day-to-day basis. They are in treatment until the end of their life. So, except for a few outliers, you know, who look really, really lucky. Bonnie Rochman So that's kind of the distinction there. So with all these different treatments that you underwent, there are short-term side effects and long-term effects of every single treatment. And then in addition to the physical and physiological side effects, you've also got emotional side effects, spiritual side effects. Often cancer can impact all sorts of relationships — romantic, parent-child. Diane Mapes Well, sexual side effects for sure. Bonnie Rochman Sexual side effects. I mean it just does not leave an area of your life untouched. Diane Mapes Your friends will dump you too. I mean, there's that as well and spouses. Oh yeah, two really good friends, their spouses were out of there. Bonnie Rochman They just couldn't handle it, it was just too heavy for them. Diane Mapes I don't know. Some people are just not comfortable with cancer. I mean, who would be, right? It's just a matter of being there for people or not. Some people aren'tequipped for that. And treatment is very, very different depending on the type of cancer that you have. I had breast cancer, that is considered a solid tumor. So the treatment for solid tumors is more like the chemotherapy, the radiation, the surgery, the anti-hormones, whether you're a prostate cancer patient or a breast cancer patient. But treatment for a blood cancer or a lymph cancer is quite different. Like if you have to do a stem cell transplant, basically that is an immune system transplant. They kill your own immune system with highly toxic chemo and then transplant somebody else's, a relative or somebody who matches into your system. But they have very, very different side effects. A lot of it comes from being severely immunocompromised. They will have side effects like GVHD, graft-versus-host disease, which can cause all kinds of issues in all different parts of the body. So there's that kind of treatment. Now things are changing a lot. As you mentioned, we've got immunotherapy. Solike an early stage solid tumor patient might get surgery, chemotherapy, radiation. Maybe they get tamoxifen or aromatase inhibitors if they're a breast cancer patient. Maybe if they are a prostate cancer patient, they might get an androgen deprivation therapy. They might be put on Lupron, like for ovarian suppression, women might get that if they still want to have kids. You'll be put on steroids. You will be put on checkpoint inhibitors maybe if you're high risk now, if you are a breast cancer patient, early stage. After chemotherapy, they commonly give patients a shot of either Neulasta or Neupogen, a colony-stimulating factor, a granulocyte colony-stimulating factor, and that boosts your white cell production. So it fights off infection because a really common side effect is you get some kind of infection because you are severely immunocompromised from your treatment, from your cancer. Bonnie Rochman So with all of these treatments that we're talking about, all this, I mean, just listening to you, I'm feeling overwhelmed. So with these different treatments, there are, in some cases, late-term side effects that we are still discovering because, let's go back to the beginning of when we started having this conversation. Because people historically haven't survived for years and years and years, we don't have the longitudinal data to even really know how these treatments impact people over 10 years, 20 years, 30 years out. And then you take immunotherapy, which is harnessing the body's own immune system to fight your cancer. And that is much newer. We really don't know what the long-term side effects are of that. And that is one reason why research is really so important. That's what we do here at Fred Hutch. Diane Mapes Yeah, I mean, if you think about how cancer treatment has changed over the years, I see it as someone who's 15 years out. When I was diagnosed, there was no MammaPrint or diagnostic tests that would tell me, you know, if I should have this treatment or that treatment. So these things have been developed since then. There were no checkpoint inhibitors, CDK4/6, for people if they were at high risk. That is new. They're using radiation in different ways, they're using chemotherapy in different ways. It's much more finessed now, much more of less is more. They are discovering and they're discovering this because of research, because they keep going back and looking and saying, do we have to give that much? How about maybe if we don't give that much? Another thing that's really common with breast cancer particularly is that when you get a mastectomy, they used to, and some surgeons continue to do this, harvest all your lymph nodes. Well, your body needs those and without your lymph node, women and men will get, you know, swelling of the limbs, lymphedema, because it cannot clear the body of all of these, the toxins and stuff. So again, that could be a short-term or a long-term effect of cancer treatment. You know, we all know the short-term stuff, chemo, you lose your hair, it grows back. You have nausea, but they have really good anti-nausea meds. So like when I had chemo, I didn't throw up once. I was very proud of that. But I assumed I would be living in the bathroom, right? Because that's what you see on TV all the time. Everybody knows it's the, you know, really skinny, pale, bald woman, but it's really not like that so much. You do have a lot of short-term stuff that you have to deal with. Nausea, hair loss, mouth sores. You know, weak fingernails, that sort of thing, because chemotherapy kills fast-growing cells like cancer and hair and mucosa. And you know that's why you get nauseous in your stomach. Then you also have these long-term issues, you know it could be the cognitive effects of chemotherapy, the old chemo brain where you're just sort of kind of foggy, the sexual side effects that we mentioned, where you lose your libido. You know, when they start you on chemotherapy, or they put you on an anti-hormone, you are in menopause. Immediately. It's like you hit it. There's no transition. You hit it like a brick wall, 60 miles an hour. So there goes the libido! There goes everything. Here come the creaky knees and the creaky joints. And I used to wake up every morning and my hands would feel like glass, like they were going to break, just shatter. So some people know about some of these, some people don't. When you're about 10 years out, you know, which is where I am 10, 15 years out. Then you have to think about things like the cardiotoxicity of chemo, what the effects are on your heart. And there are certain chemotherapies that really impact your heart and your heart functions. So you have to get checked out for that. You have to be checked out if there's any damage to your lungs. I have radiation on the left side. So that's a lung and a heart, you know. And I have to really be cognizant of that and make sure that I get scanned. I got a scan. I got a cardiac CT. And wouldn't you know it, they found some lung nodules. So now I'm seen to make sure that it's not a new primary lung cancer or metastatic disease, breast cancer in my lung. So there's always something fun you’ve got to check out. Bonnie Rochman Yeah. So that is a great way to segue to the fact that treatment, even once you are done with your treatment and you're — when did you finish your anti-hormone therapy? Five years ago? Mm-hmm. Okay. So you've been out of treatment for five years now, right? But you're still, it doesn't end. So there are side effects, after-effects, so many things can and are really changed forever. And that doesn't need to sound like, oh my God, doom and gloom, but... Diane Mapes Things are going to change things. Yeah, and it's important for people to know that cancer doesn't end when you're out of surgery, chemo, radiation, you know, whatever. You're still dealing with all the cumulative effects of all of this. And sometimes they, you, know, come back and visit you unexpectedly, you know, where you realize, you'rean unwelcome guest. Yeah, exactly. They pop up on your doorstep. Say, hey, remember me? I'm fear of recurrence. It's definitely not something that I am fussing and thinking about every day, although I do work at a cancer research center, so you know, writing stories about cancer a lot. It is top of mind, but I am not brooding and gloomy about my own cancer and the treatment and the things that are changed all the time. Yes, I am uncomfortable every day because I have implants under the muscle. And it feels like I'm wearing the most, you know, the world's most uncomfortable bra that I can never take off. Yeah, yeah, that's part of it, but I'm alive. You know, I'm here to complain about it, right? So it's just a matter of getting the tools that you need, getting the resources that you need, knowing what you're supposed to pay attention to. You know like, right now, I think I mentioned to you, I have to go to the dentist quarterly to have my teeth cleaned, because I have dry mouth permanently from chemo, you know? I have, as I said, I have a cardio-oncologist, I'm going to a lung nodule clinic, you know, my energy level is not the same as maybe it should be, right? And I also have to be aware that I have to look for signs of recurrence. Always be on the lookout for anything that might be something that needs to be explored further. Bonnie Rochman Now, how do you balance that — the evidence-based awareness that that is something you need to look out for without freaking out about every, I don't know, little twinge you might feel. Diane Mapes It's a balance, it really is. I think about the things that I'm doing to stay healthy. I probably walk four or five miles a day, I do yoga a couple times a week, a little bit of strength training, and yoga involves some meditation and breathing, and there's also medication. I'm on anti-anxiety meds, you know? Might as well throw those out there too, because I'm using all my tools, you know? And working at a cancer center, too, and having a lot of people that you know and love dealing with cancer and dying from cancer, it's anxiety-producing. But I don't sit in that place where, I don't sit in the place of fear and worry. I sit in a place of power and determination, I think, moreso. Bonnie Rochman I think it's an amazing place to end unless you have something specific that you want to add. Diane Mapes Sure. I'm trying to, you know, move forward. Just keep swimming is what I always tell people. Bonnie Rochman So this has been an awesome conversation. Diane, thanks for sharing your experience both as a patient, as a professional, and as a survivor. Next, we're going to be joined by Barb Regis, who is a PA who has really helped build the survivorship clinic here at Fred Hutch. She is a survivor herself, and I'm going to let her tell us in her own words how she made it to Seattle from Arizona, where she practiced for almost three decades. Thank you so much for joining us. I just introduced you at the end of my conversation with Diane, and I'm really interested in hearing your story. You were given a 60% chance of living five years when you were diagnosed with cancer. And I'mwondering if you could tell us about that diagnosis, what that diagnosis was, and especially what it was like to get that diagnosis both as a person and as a primary care provider. Barb Regis Thanks for the opportunity to chat with you today. Yeah, I was diagnosed with a rare form of melanoma called amelanotic melanoma back in 2018. The melanoma didn'teven look like a typical black mole, you know, it was nodular. It just didn't at all look like it. So I really wasn't too concerned when I went to my dermatologist, except for it was growing very quickly. So think about this, I'm seeing my patients and it's noontime with my team. And I get a phone call and the phone call is, you better sit down. I go, I'm sitting, so let me have it. So my friend, the dermatologist says, you have a very rare form of melanoma. We're really worried about you. We need to get you in as fast as possible for treatment. And so, you know, we need to take this really seriously. So I said, do you have people in mind that I can go to? And she's like, yeah, I have this doctor and this doctor. And these are people I had referred to in my practices before, so it was like, yeah, good, let's get it going. So I sit back and I'm with my team and I just take a deep breath, I'm like, trying to process, like, what did you just say, right? And so basically I looked at my team and I go, we've got patients to see this afternoon. And the first thing I thought of was like how do I keep it together for my patients? But more importantly, how do I go home and tell my family that I'm in trouble when we didn't think there was really anything going on. You know, it was just, it was daunting. It was crazy. So I just went in, I saw my patients for the afternoon, I went home and told my family, told my husband, basically said, here's the deal. And then I got a call and I was very blessed to be able to get into a surgeon, to an oncologist within, you know, three or four days. And so, yeah, it was crazy. As a provider, when you're somebody who diagnoses people with cancer a lot, you know, when it's your turn, it's a whole different feeling and perspective, that's for sure. Bonnie Rochman You're here now. So walk us through, how did you get from Arizona to Seattle? And I'm curious about the treatment too. Is it just surgery? Barb Regis With the treatment let me I'll tell you what happened basically was I went in and we did surgery and basically they took a huge wedge out of my arm so they were thinking they might have to do like a skin graft but we lucked out and they were able to do a closure but if you look at my arm I do look like a shark took care of business but I won at the end and then I was very blessed because it sounds terrible I was stage 3C. But I was blessed because I knew I qualified for immunotherapy. So I knew that if I was2D, I would not have qualified unless I got in a trial, but being at 3C, I would qualify. So I did immunotherapy for, you know, for a year. Things were fine. Things seemed to be great. Well, July 4th of 2020, I felt my arm right here and I went, oh my goodness, it's back. So at that point, I called up my oncologist, she goes, Barb, I just saw you two weeks ago. I go, I'm not kidding you, it's back. So I get the PET scan and luckily I was still just more involved in the arm and some lymph nodes. More surgery. Fast forward, the plan is now, from what they knew back in 2020, we would do a combination of two immunotherapies. We'd do Ipiniv and we'd do radiation. We do it all at the same time. So basically what happened was they hit me. I had radiation burns. Diane Mapes It was the immunotherapy that... Barb Regis It was, it was. Diane Mapes A reaction or something. Barb Regis So I ended up permanently with adrenal insufficiency, so I do rely on steroids for the rest of my life as a result of that. And I had colitis and I had a lot of different things. But we elected to stop three out of four, finished the radiation. And the great news is I'm now, this year, a patient at Fred Hutch, and I'm without evidence of cancer. So, it was worth it. Diane Mapes Yeah, NED — no evidence of disease. Barb Regis Yeah, it's a beautiful term, isn't it? Diane Mapes My favorite guy. Barb Regis Yes, that's right. Bonnie Rochman That's right. How many years is that since? Barb Regis It was 2020, when I really had the problems, it was right around my birthday, October, and then it's been six years. Diane Mapes Yeah, so that's great for our patients because you have a lot of experience in the newest therapies out there. So that's really beneficial for people because immunotherapy is just continuing to grow. When you went through it, it was pretty new. It was only being used for melanoma and only a few really advanced melanoma cases, correct? Right. And now they’re using it more and more in solid tumors as well. Barb Regis Keytruda, you know, was the therapy that treated Jimmy Carter back in the end, and they didn't know it was going to cross the blood-brain barrier, and it did. And now Keytruda is indicated as not necessarily first-line, but second-line, third-line for over 40 different diagnoses. So it's very exciting. I am so excited about what immunotherapy can do for patients, how much hope it gives patients, and what we're seeing in the breast cancer space with triple negative breast cancer and those kinds of things. There's so much hope and I am so grateful that I qualify because I know if I had been diagnosed a decade earlier, I can honestly say I would not be speaking with you today. And that humbles me a lot. Bonnie Rochman And additionally, you have the expertise and the firsthand experience of immunotherapy and side effects to be able to talk to your patients who are survivors of all sorts of cancers, melanoma, and anything else too. You just have that additional, I think, level of empathy that someone who hasn't gone through it wouldn't have. Barb Regis You know, we still don't know, we're learning more about the late effects and all these kinds of things. And I just share with patients, just stay the course, try to be healthy and be grateful that we have more tools in the toolbox as we have concerns with people that are not responding to some of the traditional therapies and stuff like that that we've been used to forever, that kind of thing. Bonnie Rochman So, thanks for sharing everything about your experience with having cancer, being diagnosed, being treated. We're happy you're here. We're so happy you are here. Our patients are so happy you are here. Your diagnosis, if I'm remembering correctly from when we talked last month, your diagnosis, I think it would be fair to say it directly, it's directly correlated with why you're here. Barb Regis Yeah, I've been in Arizona since I went to college and I never expected to stay there. I'm an East Coast girl. And my husband and I came this close to moving here in 1992. And the only reason we didn't move here was because my parents announced that they were going to be snowbirds in Arizona and they were coming our way and I'm like, oh great. So we had, you know, his parents, my parents, so we elected to stay to see them through. And my parents had very great longevity genes, and so my parents were in their — my mom, early 90s, my dad, late 90s — before he passed. And so while I was dealing with this diagnosis of melanoma, I was also dealing with a lot of issues with my parents, and my husband was amazing in helping me with that. But...the moment my dad passed away, I know this is going to sound terrible, but he passed away and he was 98 and a half. He had a great life. I looked at my husband and I said, if I die here, I will never forgive you. We wanted to be in Seattle so bad, so bad. We both did. We were done with the desert. 115 degrees, now I'm wearing long sleeves. I want seasons. Oh my gosh, it's fresh air here. I challenged him. I said I know we're a little bit older, but get a job. I always knew I wanted to get into the cancer space. So I actually started applying for jobs and it was like, you have no experience in the cancer space, you know, you’re primary care. That's how I ended up at Fred Hutch. It was just finally having an opportunity and an interview and somebody saying, okay, we'll take a chance on her. Bonnie Rochman So did you, did you even know what survivorship was? Had you done survivorship in Arizona? Like,what were you applying for? Barb Regis All I knew was it was for cancer survivors and I was like, you know what? I've got a lot of primary care experience. I'm a cancer survivor, thriver. I think I can talk the language. And I also knew that I had learned in the interview process that they really wanted to build the clinic and they really want to get survivorship out there and start helping it thrive. And I got a sense that they were struggling with that. So one of the things that I bring to the table is I have built practices. I built a huge practice, two practices in Arizona, my own, and then at Premise Health, I really helped build practices, build relationships. Bonnie Rochman So tell us what you're doing. What did you build? What did you put into place and then what is actually working? Barb Regis You know, someone is considered a survivor, technically, from the moment of diagnosis all the way through. But what I noticed here was people were getting invited or coming to Survivorship when they were done with active treatnebt, when they were done with surveillance, when they were way out. I was like, whoa, whoa whoa whoa, no, no no no. People need you in this program when the people feel like they need us. So I asked for latitude there. I said, if I get a patient who's in active treatment or even newly diagnosed, as long as they have a diagnosis of some sort of cancer, why can't we see them? Because there's something we can offer them, you know? And so I said just give me a chance. And so I went around and talked to some of the providers. I said hey, I know you're not referring too much. Just refer a couple of patients and just get feedback from the patients and see if it's worth it. Can you do that for me? And so I had a couple providers start taking me up on that. And I saw that the number of referrals coming from within Fred Hutch were pretty minimal. It was like, you know, less than 40% at the time. And now it's well over 60 to 70%, you know even more. And so once they realized, wait a second, these patients are getting some benefit from this. Why not? And so you know, I've had patients come to me before active treatment and say, hey, what can I do to just feel stronger and healthier as I start on this journey? So I'm really clear with them. I'm like, listen, let's talk about diet, exercise. Let's get you a nutrition appointment. Let's talk about how you can emotionally start working with this. Like, maybe we should get a counselor right now or maybe we should wait. And so you meet the patient on their terms, whatever it is that they want. We're here to serve them. So it was really fun. And so I have several people that are stage 4. I had people that have recurrences that are scared to death about what's going to happen next that I see on a regular basis. And then I see people that aren't perfect candidates, those that are transitioning from active treatment into surveillance. They're the perfect ones because they see their oncology teams all the time. They're being supported all the time. Then the oncology team is like, hey, we're done. They're NED, we've done it, ka-ching, boom, boom boom, pat myself on the back, hey, see ya. Great news, I'll see you in three months. And the patient's like, uh-oh. You can feel like you're being dropped off a cliff. And they're like, but I'm tired, but I don't feel well, like what do I do? So they're the perfect patient. They're ready to go, they're what can I do. And so, you know, it's been great. So, we're really expanding that concept across all of Fred Hutch right now. And so it's really exciting times to get that feedback from patients that they see so much value in this. Because what we're doing is just giving them a time where they can just be really open, organic about what their needs are and see how we can help them start progressing and thriving again. That's what it's all about. And so here, or here, or here. That's awesome. 60-70% of the patients seen in the clinic now are coming from Fred Hutch referrals, whereas when I started, it was much less than 50. There are self-referrals. They come from other community providers, like Swedish. Yeah, you know, some of the Kitsap area. A lot of people out in the area. Diane Mapes We'll see patients from outside. Bonnie Rochman You had mentioned you have some international patients, right? Barb Regis Yeah, it's kind of fun. We have a couple of patients from Canada, a patient from the Philippines. There's one from Vietnam and what the skinny is like, they come over here twice a year to visit family and they heard about the clinic and they self-referred. They really want to dial in on what they can do to be healthier. They want to know what the state-of-the-art recommendations are. And they know Fred Hutch is the place to go. How do you think the word is getting out? Uh, it's, you know, what I learned in practice over these years is word of mouth. You treat people well, the word gets out on the street and eventually it happens. And that's why I begged for some time because I knew at year three, which is where we're at, the clinic would be full and it would be really thriving. It takes about three years to really get it going and get that word out. You know, Cancer Lifeline is a great resource, you know, Survivor Northwest, a lot of different places are just getting the word out, we get quite a few referrals, like I said, from the islands and stuff like that. It's pretty exciting. Diane Mapes Is that Team Survivor Northwest that you're talking about, a group for women cancer survivors? Barb Regis Yeah, they're great! Diane Mapes Now, Barb, we have at Fred Hutch, not just a survivorship clinic where people can come in and see you and your colleagues, but we also have a research program that'sled by Dr. Scott Baker and Dr. Eric Chow that you've mentioned. And then we also have Dr. Vidhya Nair who is also part of that. Survivorship is going to be divvied up a little bit differently now moving forward here at Fred Hutch. Barb Regis Okay, I'm going to do the best I can. So we're really thrilled to have Dr. Nair and Theresa Wittenberg to join us. And what they're doing is they are working with the different service lines to start integrating survivorship in the service lines when people transition from active treatment. Diane Mapes Just for our audience, when you say service line, that's not a term that most people use. You're talking about the different clinics, like a clinic, a lung cancer clinic. Yeah, different specialties. The different specialties. Barb Regis Yeah, the different specialties. It's going to be a program that's going to take a long time to launch because they're being very mindful and methodical about it. So they'restarting with, you know, GU first. They're launching that. Diane Mapes Genitourinary. Barb Regis Yeah, so you know, our prostate cancer folks, our bladder cancer folks, those kinds of things. They're sharing with that group first and then they're going todetermine which groups go next. And so they're really setting the stage for what this is going to look like system-wide across Fred Hutch. But you know it's something that's not going to happen overnight. It's going to take a while. But the idea is just like you know when you're in surveillance you just start talking about survivorship topics along with this and to help patients get more confident. Bonnie Rochman There was something that you said when we spoke initially which really stuck with me. And I'm wondering if you can talk a little bit about how you as a provider care for patients coming into survivorship. Specifically, you said you start by saying you're sorry. You don't even turn on the computer because you are so steeped in their story. That you know it upside down, back and forth, and you just talk like you're talking to a friend. So I was wondering if you could expand upon both of those. Barb Regis Yeah, I will be totally transparent. I don't ever turn on the computer when I'm in person with a patient. And the reason I do that is because I feel like I'm not treating the computer, I'm treating the patient. And I want to gain their confidence and I want to gain their trust and their knowledge. And I want them to know that I do know them inside out. Our nurse spends three to four hours on some of these patients. I spend an additional hour or so. And we really drill down to really get a feeling for each patient, so it's really nice and organic. You know, it's one of those things where you walk in the room and you just give them that chance to just tell you what they want to say. And there's times where patients have not had the opportunity to say things that they just need to get off their chest. So I will give you an example. A patient who shared with me that she had a year and a half of delay in diagnosis. And the reason was is because she was told, quote unquote, you are too young to get breast cancer. Yep. So she was probably initially stage 1. And by the time she was diagnosed, she was stage 3C. And unfortunately it made a difference in whether or not she was going to be able to bear children moving forward. She needed to get that off her chest once and for all so that she could finally start processing and healing. That's why when I start each visit, I say, you know, basically I go, how are you holding up? How are you? And usually that's when it starts. And so at the end, I look at them and I go, I'mreally sorry this happened. I'm deeply sorry. But now that we've chatted about this, we need to start thinking about moving forward. How can I help you do that? And it'svery powerful. It's time when the tissues come out. It's a time when someone will say, You know how many people I've seen and no one's ever had the courage or thought about saying, I'm sorry. And I learned early on in my career, you're humble and it's okay to say you're sorry. It really is. And people sense, yeah, we're all human here, but they need to be validated. And they will say thank you. And sometimes they'll say, I need you to hug me. Is that okay? And I go, yeah sure. So do you really want to have the computer on in the room when that happens? Does it mean that I spend a heck of a lot more time doing my notes because I replayed the tape and all this and my notes are pretty extensive? It's worth it to me. Diane Mapes So, Barb, what are some of the things that you would recommend if someone came in and they had, in my case, I had double mastectomy, chemo, radiation, 10 years of anti-hormone treatment? What would be your concern? Barb Regis Well, I'll tell you based on whatever therapy you would have, you know, I'd want to, you know, make sure that you're aware of things like secondary cancers. So you know with certain kinds of chemotherapies like cyclophosphamide, for example, secondary cancers, radiation. So I want you to know that and your primary care provider know that and in the care plan, which I send to them, I go, please make sure you're doing a CBC every year. And so what happens sometimes is like, you'll see a little ditzel and you'll go, ah, it's probably nothing. I want the primary care provider to remember, oh, this person was on a certain therapy, I should work it up. And so with medications like Adriamycin, for example, if you're having issues with exercise or shortness of breath, chest pain, something doesn't feel right, please make sure you let your care provider know. And I recommend for example to the primary care provider, have a baseline EKG in the chart. To have something to work with so that if someone does come in with something, we'll have more data to work, with those kinds of things. Diane Mapes Make lifestyle changes too. They could get out and exercise more. They could look at dietary changes to make sure they're not taking in too much, you know, saturated fat or something like that. You got it. That would be the cardiovascular disease risk. Barb Regis Yep, and what's neat is if people are interested, I'm able to refer to one of our nutritionists for another appointment to meet them where they are, not only to talk about the cancer part of it, but a lot of the patients are really into working out and doing things, and so they're really curious about their macros and things like that. So we can give them kind of like a two-for-one there. So I really emphasize that. Exercise, absolutely, you know, is something we talk about, but I really want to make sure that patients don't do too many things too fast. We have guidelines, I get it, but I want to see what the baseline is and then very systematically, let's start, you know, working ourselves up. Let's not do things too fast. I don't want you to injure yourself and also let's, you know, be mindful. You know, we're recovering. We're not what we were before necessarily. And in normal aging, it's the same way, right? I'm a huge proponent for acupuncture for some of our folks that have hot flashes, peripheral neuropathy, someof the more mental health needs. You know, finding a good acupuncturist to work with is a game changer for a lot of folks. Sleep is juice. Sleep is another one. Yep. Bonnie Rochman I wonder — and thank you for all the time you spent with us, I know you actually have real patients to go tend to — so this is my last question. I don't know if you have anything additional that you want to ask, but I'm wondering when you meet with patients, do you tell them that you yourself are a survivor and why or why not? Barb Regis Yep, that's the first thing we do. When I introduce myself, I have the same thing I do, especially with telemed patients. I show them my ID and then I say to them, you know, we're going to have hopefully a really great conversation today, but I think if it's okay with you, can I give you a little background about myself and why I'm doing this role? And they're like, yeah, sure. And so I spend probably about two minutes telling them and sharing with them what I shared with you today. And then I always say,enough about me. Let’s not talk about me anymore. This appointment is all about you. And then, I segue into, how are you holding up? Diane Mapes That's great. Wow. I imagine that there are quite a few people here at Fred Hutch who went through cancer themselves and then came to work here. You, me, I know some of the other folks in our department in communications and marketing and a lot of the other folks that are staff at Fred Hutch. You want to do your part to take this disease down. Barb Regis That's right. One patient at a time, we're getting there too. There's so much hope. Bonnie Rochman Thank you, Barb. This has been really, really helpful. And Barb, thank you so much for joining us. This has been amazing. I'm Bonnie Rochman. Diane Mapes I am Diane Mapes. Fred Hutch News. Thank you.

First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations There was an estimated 77% probability of remaining progression-free at three years with TALZENNA plus XTANDI Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in men with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC). These results will be presented today in a late-breaking oral presentation (Abstract LBA5007) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in TheNew England Journal of Medicine. TALZENNA plus XTANDI demonstrated a 52% reduction in the risk of radiographic progression or death compared to placebo plus XTANDI (Hazard Ratio [HR] of 0.48; 95% Confidence Interval [CI], 0.36–0.65; p ˂ 0.0001). At three years, radiographic progression-free survival (rPFS) rates were estimated at 77% in patients treated with TALZENNA plus XTANDI versus 56% in patients treated with placebo plus XTANDI. With a median follow-up of over 37 months, median rPFS was not reached in the TALZENNA plus XTANDI arm and was 46 months with placebo and XTANDI. The rPFS benefit observed with TALZENNA plus XTANDI was consistent across pre-specified groups with various patient and disease characteristics, including age, Gleason score, geographic region, prostate-specific antigen (PSA) level, and BRCA vs. non-BRCA HRR gene alteration status. At three years, rPFS rates were estimated at 77% vs. 49% in patients with cancer harboring BRCA alterations (HR, 0.37; 95% CI, 0.22–0.61) and 76% vs. 60% in patients with cancer with non-BRCA alterations (HR, 0.57; 95% CI, 0.39–0.82), compared with placebo plus XTANDI. “Delaying progression to castration‑resistant disease, the most symptomatic and lethal phase of prostate cancer, remains a significant challenge to patients with mCSPC – especially to those with HRR gene alterations, who often experience poorer outcomes,” said Neeraj Agarwal, M.D., FASCO, Presidential Chair of Cancer Research at Huntsman Cancer Institute at the University of Utah and global lead investigator for TALAPRO-3. “With more than three years of follow‑up and median radiographic progression‑free survival not reached, TALZENNA plus XTANDI demonstrated durable disease control across a broad HRR‑altered population, including patients with BRCA and non‑BRCA alterations. These findings underscore the importance of genetic testing as part of routine care and highlight the potential for TALZENNA plus XTANDI to meaningfully improve the outcomes of patients with HRRm mCSPC.” Interim overall survival (OS) results showed a strong trend toward improved OS, a key secondary endpoint, with median OS not reached in either treatment arm (HR, 0.77; 95% CI, 0.56–1.04; p = 0.09). TALZENNA plus XTANDI also improved time to PSA progression (HR, 0.51; 95% CI, 0.37–0.71; p < 0.0001) and time to subsequent anti-cancer therapy (HR, 0.51; 95% CI, 0.38–0.70; p < 0.0001) vs. placebo plus XTANDI. The trial remains ongoing, and OS will be formally assessed at the final analysis. In TALAPRO-3, the safety profile of TALZENNA plus XTANDI was consistent with the known profiles of each agent, and no new safety signals were identified. The most common treatment-emergent adverse events (TEAEs) in the TALZENNA plus XTANDI group were anemia, fatigue, decreased neutrophil count, and asthenia. The most common grade 3 or higher TEAE was anemia, reported by 51% in the TALZENNA plus XTANDI group and 3% in the control group. Five percent of patients discontinued TALZENNA due to anemia. TEAEs were generally manageable with dose modifications and supportive care as needed. “Men with HRR gene-mutated metastatic prostate cancer face significant challenges, with faster disease progression and limited treatment options, making it critical to intervene as early in the course of disease as possible,” said Jeff Legos, Chief Oncology Officer, Pfizer. “The benefit seen with TALZENNA plus XTANDI across a full spectrum of HRR gene alterations reinforces its potential to fundamentally change clinical practice, giving patients significantly more time before disease progression as compared to the current standard of care." Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.5 million new cases diagnosed globally1 and 330,000 new cases anticipated in the United States in 2026.2 mCSPC is a form of advanced prostate cancer that has spread beyond the prostate but is still sensitive to androgen deprivation therapy.3 Approximately 5–10% of newly diagnosed cases are mCSPC,4,5 and up to 30% of these patients harbor HRR gene alterations.6 TALZENNA plus XTANDI in HRR gene-mutated mCSPC is an investigational treatment regimen. The results from TALAPRO-3 are being discussed with global health authorities to potentially expand the combination regimen’s existing indication. TALZENNA plus XTANDI is currently approved in more than 60 countries, including in the U.S. for adults with HRR gene-mutated mCRPC and in the European Union for adults with mCRPC in whom chemotherapy is not clinically indicated. Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented at ASCO, which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries. About TALAPRO-3 The Phase 3 TALAPRO-3 trial is a multicenter, randomized, double-blind, placebo-controlled study that enrolled 599 patients with mCSPC (with ≤3 months of ADT [chemical or surgical] with or without an approved ARPI in the mCSPC setting) at sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. Patients with histologically/cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, small cell, or signet cell features and with alterations in one or more HRR genes (as per HRR12 gene panel) in the trial were randomized to receive TALZENNA 0.5 mg/day plus XTANDI 160mg/day, or placebo plus XTANDI 160mg/day. The primary endpoint of the trial is investigator-assessed rPFS, defined as the time from the date of randomization to radiographic progression in soft tissue per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or in bone per Prostate Cancer Working Group 3 (PCWG3) criteria by investigator assessment, or death, whichever occurs first. Secondary endpoints include OS, objective response rate, duration of response, and patient-reported outcomes. For more information on the TALAPRO-3 trial (NCT04821622), go to www.clinicaltrials.gov. About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. TALZENNA was initially approved in the U.S., EU, and multiple other regions as a single agent for the treatment of adult patients with deleterious or suspected deleterious gBRCAm HER2-negative locally advanced or metastatic breast cancer. TALZENNA in combination with XTANDI was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC in June 2023. The combination was also approved by the European Commission in January 2024 for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. TALZENNA in combination with XTANDI is approved in more than 60 countries, indications vary by country. TALZENNA® (talazoparib) Indication in the U.S. TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: HRR gene-mutated mCRPC: In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Breast Cancer: As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. TALZENNA® (talazoparib) Important Safety Information WARNINGS and PRECAUTIONS Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received TALZENNA. Overall, MDS/AML has been reported in 0.4% (3 out of 788) of solid tumor patients treated with TALZENNA as a single agent in clinical studies. In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) patients treated with placebo and enzalutamide. The durations of TALZENNA treatment in these 5 patients prior to developing MDS/AML were 0.3, 1, 2, 3, and 5 years. Most of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous chemotherapy. Monitor blood counts monthly during treatment with TALZENNA. For prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If counts do not recover within 4 weeks, refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue TALZENNA. Myelosuppression consisting of anemia, neutropenia, and/or thrombocytopenia, have been reported in patients treated with TALZENNA. In TALAPRO-2, Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 48%, 19%, and 9% of patients receiving TALZENNA and enzalutamide. Forty-two percent of patients (216/511) required a red blood cell transfusion, including 25% (127/511) who required more than one transfusion. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 8%, 3%, and 0.4% of patients. Withhold TALZENNA until patients have adequately recovered from hematological toxicity caused by previous therapy. Monitor blood counts monthly during treatment with TALZENNA. If hematological toxicities do not resolve within 28 days, discontinue TALZENNA and refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. Embryo-Fetal Toxicity TALZENNA can cause fetal harm when administered to pregnant women. Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 4 months following the last dose of TALZENNA. ADVERSE REACTIONS Serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each). The most common adverse reactions (≥ 10%, all Grades), including laboratory abnormalities, for patients in the TALAPRO-2 study who received TALZENNA with enzalutamide vs patients receiving placebo with enzalutamide were hemoglobin decreased (79% vs 34%), neutrophils decreased (60% vs 18%), lymphocytes decreased (58% vs 36%), fatigue (49% vs 40%), platelets decreased (45% vs 8%), calcium decreased (25% vs 11%), nausea (21% vs 17%), decreased appetite (20% vs 14%), sodium decreased (22% vs 20%), phosphate decreased (17% vs 13%), fractures (14% vs 10%), magnesium decreased (14% vs 12%), dizziness (13% vs 9%), bilirubin increased (11% vs 7%), potassium decreased (11% vs 7%), and dysgeusia (10% vs 4.5%). Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%). DRUG INTERACTIONS Coadministration with P-gp inhibitors The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor. Coadministration with BCRP inhibitors Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a BCRP inhibitor. Coadministration of TALZENNA with BCRP inhibitors may increase talazoparib exposure, which may increase the risk of adverse reactions. USE IN SPECIFIC POPULATIONS Males of Reproductive Potential Based on animal studies, TALZENNA may impair fertility. Renal Impairment The recommended dosage of TALZENNA for patients with moderate renal impairment (CLcr 30 - 59 mL/min) is 0.35 mg taken orally once daily with enzalutamide. The recommended dosage of TALZENNA for patients with severe renal impairment (CLcr 15 - 29 mL/min) is 0.25 mg taken orally once daily with enzalutamide. No dose adjustment is required for patients with mild renal impairment. TALZENNA has not been studied in patients requiring hemodialysis. Please see full U.S. Prescribing Information and Patient Information for TALZENNA® (talazoparib) at www.TALZENNA.com. About XTANDI® (enzalutamide) XTANDI (enzalutamide) is an androgen receptor pathway inhibitor. XTANDI is a standard of care and has received regulatory approvals in one or more countries around the world for use in men with metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR). XTANDI is currently approved for one or more of these indications in more than 80 countries, including in the United States, European Union and Japan. Over 1.5 million patients have been treated with XTANDI globally.7 About XTANDI® (enzalutamide) and Important Safety Information XTANDI (enzalutamide) is indicated for the treatment of patients with: castration-resistant prostate cancer (CRPC) metastatic castration-sensitive prostate cancer (mCSPC) nonmetastatic castration sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) Important Safety Information Warnings and Precautions Seizure occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following predisposing factors: use of medications that may lower the seizure threshold, history of traumatic brain or head injury, history of cerebrovascular accident or transient ischemic attack, and Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection. Advise patients of the risk of developing a seizure while taking XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment. Posterior Reversible Encephalopathy Syndrome (PRES) There have been reports of PRES in patients receiving XTANDI. PRES is a neurological disorder that can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably MRI. Discontinue XTANDI in patients who develop PRES. Hypersensitivity reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with XTANDI in eight randomized clinical trials. Pharyngeal edema has been reported in post-marketing cases. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek medical care. Permanently discontinue XTANDI for serious hypersensitivity reactions. Ischemic Heart Disease In the combined data of five randomized, placebo-controlled clinical studies, ischemic heart disease occurred more commonly in patients on the XTANDI arm compared to patients on the placebo arm (3.5% vs 2%). Grade 3-4 ischemic events occurred in 1.8% of patients on XTANDI versus 1.1% on placebo. Ischemic events led to death in 0.4% of patients on XTANDI compared to 0.1% on placebo. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue XTANDI for Grade 3-4 ischemic heart disease. Falls and Fractures occurred in patients receiving XTANDI. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents. In the combined data of five randomized, placebo-controlled clinical studies, falls occurred in 12% of patients treated with XTANDI compared to 6% of patients treated with placebo. Fractures occurred in 13% of patients treated with XTANDI and in 6% of patients treated with placebo. Embryo-Fetal Toxicity The safety and efficacy of XTANDI have not been established in females. XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with XTANDI and for 3 months after the last dose of XTANDI. Dysphagia or Choking Severe dysphagia or choking, including events that could be life-threatening requiring medical intervention or fatal, can occur due to XTANDI product size. Advise patients to take each capsule or tablet whole with a sufficient amount of water to ensure that all medication is successfully swallowed. Consider use of a smaller tablet size of XTANDI in patients who have difficulty swallowing. Discontinue XTANDI for patients who cannot swallow capsules or tablets. Interference with Immunoassay Measurement of Digoxin XTANDI can interfere with certain digoxin immunoassays (e.g., Chemiluminescent Microparticle Immunoassays), resulting in falsely elevated digoxin plasma concentration results. Notify the laboratory conducting the digoxin plasma concentration assay to use an appropriate method in patients receiving XTANDI and digoxin. Adverse Reactions (ARs) In the data from the five randomized placebo-controlled trials, the most common ARs (≥ 10%) that occurred more frequently (≥ 2% over placebo) in XTANDI-treated patients were musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, fall, fracture, and headache. In the bicalutamide-controlled study, the most common ARs (≥ 10%) reported in XTANDI-treated patients were asthenia/fatigue, back pain, musculoskeletal pain, hot flush, hypertension, nausea, constipation, diarrhea, upper respiratory tract infection, and weight loss. In EMBARK, the placebo-controlled study of nonmetastatic CSPC (nmCSPC) with high-risk biochemical recurrence (BCR) patients, Grade 3 or higher adverse reactions during the total duration of treatment were reported in 46% of patients treated with XTANDI plus leuprolide, 50% of patients receiving XTANDI as a single agent, and 43% of patients receiving placebo plus leuprolide. Permanent treatment discontinuation due to adverse reactions during the total duration of treatment as the primary reason was reported in 21% of patients treated with XTANDI plus leuprolide, 18% of patients receiving XTANDI as a single agent, and 10% of patients receiving placebo plus leuprolide. Lab Abnormalities: Lab abnormalities that occurred in ≥ 5% of patients, and more frequently (> 2%) in the XTANDI arm compared to placebo in the pooled, randomized, placebo-controlled studies are hemoglobin decrease, neutrophil count decreased, white blood cell decreased, hyperglycemia, hypermagnesemia, hyponatremia, hypophosphatemia, and hypercalcemia. Hypertension: In the combined data from five randomized placebo-controlled clinical trials, hypertension was reported in 14.2% of XTANDI patients and 7.4% of placebo patients. Hypertension led to study discontinuation in < 1% of patients in each arm. Drug Interactions Effect of Other Drugs on XTANDI Avoid coadministration with strong CYP2C8 inhibitors. If coadministration cannot be avoided, reduce the dosage of XTANDI. Avoid coadministration with strong CYP3A4 inducers. If coadministration cannot be avoided, increase the dosage of XTANDI. Effect of XTANDI on Other Drugs Avoid coadministration with certain CYP3A4, CYP2C9, and CYP2C19 substrates for which minimal decrease in concentration may lead to therapeutic failure of the substrate. If coadministration cannot be avoided, increase the dosage of these substrates in accordance with their Prescribing Information. In cases where active metabolites are formed, there may be increased exposure to the active metabolites. Please access this link for XTANDI’S US Full Prescribing Information for additional safety information. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. About the Pfizer/Astellas Collaboration In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE: PFE), and Astellas (TSE: 4503) entered into a global agreement to jointly develop and commercialize XTANDI® (enzalutamide). The companies jointly commercialize XTANDI in the United States, and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States. Disclosure Notice The information contained in this release is as of May 30, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology, TALZENNA and XTANDI, including their potential benefits, the TALAPRO-3 results, and plans to discuss the results with global health authorities to potentially expand the TALZENNA indication, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of TALZENNA in combination with XTANDI;the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether the TALAPRO-3 trial will meet the key secondary endpoint for overall survival; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications for TALZENNA, XTANDI or a combination may be filed in any jurisdictions for any potential indications; whether and when any such applications for TALZENNA, XTANDI or a combination that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether TALZENNA, XTANDI or a combination will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of TALZENNA, XTANDI or a combination; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. References Media Contact: PfizerMediaRelations@Pfizer.com Investor Contact: IR@Pfizer.com Source: Pfizer Inc.